This study is accepting new patients by invitation only

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

a study on Hematologic Malignancy Hematologic Neoplasms

Summary

Location
at UC Davis UCLA UCSD UCSF
Dates
study started
study ends around
Principal Investigator
by John M. Timmerman, MD (ucla)Aaron Logan (ucsf)
Headshot of John M. Timmerman
John M. Timmerman
Headshot of Aaron Logan
Aaron Logan

Description

Summary

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.

Keywords

Solid and Hematological Malignancies, Hematologic Neoplasms, axicabtagene ciloleucel, brexucabtagene autoleucel, Anitocabtagene autleucel, KITE-753, KITE-197, KITE-363, Axicabtagene Ciloleucel (KTE-C19), Brexucabtagene Autoleucel (KTE-X19)

Eligibility

You can join if…

  • The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
  • The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
  • In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

You CAN'T join if...

none

Locations

  • UC San Diego Moores Cancer Center
    La Jolla 5363943 California 5332921 92093 United States
  • University of California Los Angeles
    Los Angeles 5368361 California 5332921 90095 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento 5389489 California 5332921 95817 United States
  • University of California, San Francisco Medical Center
    San Francisco 5391959 California 5332921 94143 United States
  • Children's Hospital Los Angeles
    Los Angeles 5368361 California 5332921 90027 United States
  • Children's Hospital of Orange County
    Orange 5379513 California 5332921 92868 United States
  • City of Hope
    Duarte 5344147 California 5332921 91010 United States
  • Stanford University
    Palo Alto 5380748 California 5332921 94305 United States

Lead Scientists at University of California Health

  • John M. Timmerman, MD (ucla)
    Professor, Medicine. Authored (or co-authored) 75 research publications
  • Aaron Logan (ucsf)
    Dr. Aaron Logan is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Kite, A Gilead Company
Links
Gilead Clinical Trials Website
ID
NCT05041309
Study Type
Observational
Participants
Expecting 1000 study participants
Last Updated